These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35800514)
21. Cost-effectiveness analysis of Japanese Encephalitis (JE) vaccination program in Bali Province, Indonesia. Putri WCWS; Sawitri AAS; Yuliyatni PCD; Ariawan IMD; Meyta H; Labiba SU; Suwarba IGNM; Sutarsa IN Vaccine; 2023 Nov; 41(47):6930-6940. PubMed ID: 37866992 [TBL] [Abstract][Full Text] [Related]
22. Data from the World Health Organization (WHO) National Network Laboratory for Japanese Encephalitis. Borthakur A; Das N; Bora B J Glob Infect Dis; 2013 Apr; 5(2):76-9. PubMed ID: 23853435 [TBL] [Abstract][Full Text] [Related]
23. An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China. Yin Z; Beeler Asay GR; Zhang L; Li Y; Zuo S; Hutin YJ; Ning G; Sandhu HS; Cairns L; Luo H; Vaccine; 2012 Aug; 30(37):5569-77. PubMed ID: 22698453 [TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833 [TBL] [Abstract][Full Text] [Related]
25. Insecticide resistance status of three vectors of Japanese encephalitis in east central India. Sahu SS; Sonia T; Dash S; Gunasekaran K; Jambulingam P Med Vet Entomol; 2019 Jun; 33(2):213-219. PubMed ID: 30565276 [TBL] [Abstract][Full Text] [Related]
26. Recurrence of Japanese encephalitis epidemic in Wuhan, China, 2009-2010. Hu Q; Chen B; Zhu Z; Tian J; Zhou Y; Zhang X; Zheng X PLoS One; 2013; 8(1):e52687. PubMed ID: 23326348 [TBL] [Abstract][Full Text] [Related]
27. Improving community coverage of Japanese encephalitis vaccination: lessons learned from a mass campaign in Battambang Province, Cambodia. Thigpen MC; Sarath S; Soeung SC; Vichit O; Kitsutani P; Sandhu H; Gregory C; Fischer M; Morn C; Hills SL BMC Public Health; 2022 Dec; 22(1):2244. PubMed ID: 36456999 [TBL] [Abstract][Full Text] [Related]
28. Epidemiology of Japanese encephalitis in the Philippines prior to routine immunization. Lopez AL; Raguindin PF; Aldaba JG; Avelino F; Sy AK; Heffelfinger JD; Silva MWT Int J Infect Dis; 2021 Jan; 102():344-351. PubMed ID: 33127505 [TBL] [Abstract][Full Text] [Related]
29. The current burden of Japanese encephalitis and the estimated impacts of vaccination: Combining estimates of the spatial distribution and transmission intensity of a zoonotic pathogen. Moore SM PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009385. PubMed ID: 34644296 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Japanese encephalitis SA 14-14-2 live attenuated vaccine among Indian children: Retrospective 1:4 matched case-control study. Tandale BV; Khan SA; Kushwaha KP; Rahman H; Gore MM; J Infect Public Health; 2018; 11(5):713-719. PubMed ID: 29703709 [TBL] [Abstract][Full Text] [Related]
31. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China. Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360 [TBL] [Abstract][Full Text] [Related]
32. Surveillance for Japanese encephalitis in Vietnam, 1998-2007. Yen NT; Duffy MR; Hong NM; Hien NT; Fischer M; Hills SL Am J Trop Med Hyg; 2010 Oct; 83(4):816-9. PubMed ID: 20889870 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of Japanese encephalitis vaccination among children in central India. Tandale BV; Khude PM; Deshmukh PS; Narang R; Qazi MS; Padmaja GV; Jain M; Jain D; Guduru VK; Deshmukh PR; Raut AV; Narlawar UW; Jha PK; Rajderkar SS; J Med Virol; 2023 Jan; 95(1):e28399. PubMed ID: 36512338 [TBL] [Abstract][Full Text] [Related]
34. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Chotpitayasunondh T; Pruekprasert P; Puthanakit T; Pancharoen C; Tangsathapornpong A; Oberdorfer P; Kosalaraksa P; Prommalikit O; Tangkittithaworn S; Kerdpanich P; Techasaensiri C; Korejwo J; Chuenkitmongkol S; Houillon G Vaccine; 2017 Jan; 35(2):299-304. PubMed ID: 27903416 [TBL] [Abstract][Full Text] [Related]
35. Environmental factors and spatiotemporal distribution of Japanese encephalitis after vaccination campaign in Guizhou Province, China (2004-2016). Zhao S; Li Y; Fu S; Liu M; Li F; Liu C; Yu J; Rui L; Wang D; Wang H BMC Infect Dis; 2021 Nov; 21(1):1172. PubMed ID: 34809606 [TBL] [Abstract][Full Text] [Related]
36. Childhood encephalitis hospitalizations associated with virus agents in medium-endemic states in India. Tandale BV; Bondre VP; Sapkal GN; Gopalkrishna V; Gurav YK; Rao RK; Qazi MS; Narang R; Guduru VK; Niswade AK; Jain M; J Clin Virol; 2021 Nov; 144():104970. PubMed ID: 34560339 [TBL] [Abstract][Full Text] [Related]
37. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Nasveld PE; Ebringer A; Elmes N; Bennett S; Yoksan S; Aaskov J; McCarthy K; Kanesa-thasan N; Meric C; Reid M Hum Vaccin; 2010 Dec; 6(12):1038-46. PubMed ID: 21150279 [TBL] [Abstract][Full Text] [Related]
38. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. Siraprapasiri T; Sawaddiwudhipong W; Rojanasuphot S Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):143-8. PubMed ID: 9322297 [TBL] [Abstract][Full Text] [Related]
39. Assessment of effectiveness of Japanese encephalitis vaccination in West Bengal, India using sample positivity rate as an alternate measure. Chakraborty D; Banerjee S; Maji D; Dey TK; Vaitheeswaran K; Mondal P; Biswas P; Debnath F; Chatterjee P J Vector Borne Dis; 2021; 58(3):199-205. PubMed ID: 35170456 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. Capeding MR; Alberto E; Feser J; Mooney J; Tang Y; Audet SA; Beeler JA; Ellison DW; Zhang L; Letson GW; Neuzil KM; Marfin AA Vaccine X; 2020 Dec; 6():100074. PubMed ID: 33005887 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]